This Saturday, October 25, 2025, BullFrog AI, Inc. and Bimergen Energy Corp. will be featured on the RedChip Small Stocks, Big Money™ show, airing at 7 p.m. Eastern Time on Bloomberg TV. This program provides companies with a platform to share insights into their operations and strategic developments.
Vin Singh, the CEO of BullFrog AI, will discuss the company's innovative approach to drug development utilizing its AI-driven platform, BullFrog Data Networks™. This platform, powered by the bfLEAP™ causal AI engine, is set to enhance drug discovery, allowing biopharma clients to accelerate development while reducing clinical trial failures.
During the interview, Singh will highlight a recent collaboration with Sygnature Discovery, which is expected to generate between $15 million and $30 million in revenue through 2028. He will also discuss the introduction of an enterprise-grade Data Networks Solutions Library, expanding the company’s market reach.
Robert J. Brilon, co-CEO of Bimergen Energy, will outline the company’s strategy for expanding its utility-scale battery energy storage system (BESS) projects. As demand for electricity rises in the U.S., Bimergen is developing 23 projects with a total planned capacity of approximately 2.0 GW across major power markets.
Brilon will detail the company's flagship 100 MW Redbird project in Texas, which aims to secure long-term offtake agreements and utilize federal investment tax credits to offset up to 50% of project capital expenditures. With expected revenues nearing $400 million, Bimergen is positioning itself as a significant player in enhancing grid reliability.
Both interviews will provide insights not only into the companies' current strategies but also their potential for future growth in their respective sectors. Investors are advised to tune in to assess how these developments may influence market performance.
The RedChip Small Stocks, Big Money show provides a valuable platform for BullFrog AI and Bimergen Energy to reach a broad audience of potential investors. It enhances visibility for both companies, showcasing their innovative strategies in drug development and energy storage, respectively.
BullFrog AI leverages a scalable AI-driven platform, BullFrog Data Networks™, that significantly accelerates the drug discovery process. By utilising its proprietary bfLEAP™ causal AI engine, the company can optimise clinical trials and streamline therapeutics development, potentially leading to higher success rates in drug development.
BullFrog AI has secured a global collaboration with Sygnature Discovery, projecting revenues of $15-$30 million through 2028, alongside launching an enterprise-grade Data Networks Solutions Library. These achievements underline the company's growth potential in the substantial biopharma R&D market.
Bimergen Energy is advancing its utility-scale battery energy storage system (BESS) projects to meet the increasing U.S. electricity demand. With 23 development-stage projects totalling approximately 2.0 GW of planned capacity, the company positions itself well within the growing energy storage sector.
Bimergen Energy is focused on advancing its flagship 100 MW Redbird project and securing long-term offtake agreements with institutional partners. The utilisation of federal investment tax credits to monetise project CapEx further enhances its financial strategy.
Bimergen Energy anticipates revenues of up to $400 million from its development pipeline, signalling substantial growth potential in a market bolstered by electrification and renewable energy integration.
RedChip Companies offers comprehensive investor relations and media services tailored for microcap and small-cap firms, enhancing their market presence through a variety of channels and strategies designed to attract institutional and retail investors.
AI is central to BullFrog AI's strategy, as it utilises machine learning and causal AI to analyse complex biological data. This innovative approach aims to reduce failure rates in clinical trials and expedite drug development processes, reflecting the company's commitment to leveraging technology for advancement in biopharma.